Enterococci infection have been treated with cell wall active agents in combination with an aminoglycoside as the synergic effect overcomes the intrinsic resistance exhibited by Enterococci. High level aminoglycoside resistance leads to synergy resistance and treatment failure.The present study was conducted to determine the prevalence of high level aminoglycoside resistance among isolates of enterococci from urine sampleA total of 147 Enterococci isolates were included in this study. High Level Aminoglycoside Resistance (HLAR) was determined by agar dilution method and E test. Of the total isolates, 81.63% were Enterococcus faecalis, 14.29% were Enterococcus faecium and 4.08% were Enterococcus avium. 60(40.82%) were found to be resistant to Ampicillin, 76(51.70%) to High LeveGentamicin (HLG), 24(16.33%) to Nitrofurantoin by disk diffusion method. Out of 120 E.faecalis isolates, 39(32.50%) were resistant to Ampicillin and 57(47.50%) to High Level Gentamicin.Among the E.faecium isolates studied, 18(85.71%) were resistant to Ampicillin, 12(57.14%) to High Level Gentamicin. High level gentamicin resistance (MIC ≥2000µg/ml) was seen in 22.45 % isolates by agar dilution method. By E test 55 % E.faecalis isolates and 71.43% E.faecium were with a Minimum Inhibitory Concentration(MIC) of ≥1024µg/ml of Gentamicin.Monitoring of HLAR in Enterococci should be carried out by high content aminoglycoside disk and agar screen method.
Impact Factor
2022: 6.012
This work is licensed under a